Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Other Operating Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Other Operating Expenses data on record, last reported at $11000.0 in Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 99.06% year-over-year to $11000.0; the TTM value through Sep 2025 reached $996000.0, down 50.79%, while the annual FY2024 figure was $2.1 million, 70.08% up from the prior year.
  • Other Operating Expenses reached $11000.0 in Q3 2025 per BTAI's latest filing, down from $107000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.2 million in Q3 2024 and bottomed at -$244000.0 in Q4 2022.
  • Average Other Operating Expenses over 4 years is $256000.0, with a median of $62000.0 recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 12725.0% in 2023, then plummeted 99.06% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at -$244000.0 in 2022, then surged by 391.8% to $712000.0 in 2023, then rose by 21.35% to $864000.0 in 2024, then plummeted by 98.73% to $11000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $11000.0 in Q3 2025, $107000.0 in Q2 2025, and $14000.0 in Q1 2025.